CN Patent

CN121419983A — 基于小脑蛋白的kras降解protac及其相关用途

Assigned to Arvinas Inc · Expires 2026-01-27 · 0y expired

What this patent protects

本文提供了靶向KRas并且因此可用于治疗癌症的化合物。

USPTO Abstract

本文提供了靶向KRas并且因此可用于治疗癌症的化合物。

Drugs covered by this patent

Lumakras (SOTORASIB) · Amgen

Patent Metadata

Patent number: CN121419983A
Jurisdiction: CN
Classification: —
Expires: 2026-01-27
Drug substance claim: No
Drug product claim: No
Assignee: Arvinas Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.